Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 14/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448891 | 1.00 | GRIA2 (1.00) | GRIA2KCNH2GRIA4 | |
| SCHEMBL4955216 | 1.00 | GRIA2 (1.00) | GRIA2KCNH2GRIA4 | |
| SCHEMBL4958666 | 0.84 | GRIA2 (1.00) | GRIA2KCNH2GRIA4 | |
| SCHEMBL4958102 | 0.84 | GRIA2 (1.00) | GRIA2KCNH2GRIA4 | |
| SCHEMBL15933105 | 0.84 | GRIA2 (1.00) | GRIA2KCNH2GRIA4 | |
| SCHEMBL4958664 | 0.84 | GRIA2 (1.00) | GRIA2KCNH2GRIA4 | |
| SCHEMBL5451223 | 0.84 | GRIA2 (1.00) | GRIA2KCNH2GRIA4 | |
| SCHEMBL5457733 | 0.82 | GRIA2 (0.70) | GRIA2KCNH2GRIA4 | |
| SCHEMBL5457734 | 0.82 | GRIA2 (0.70) | GRIA2KCNH2GRIA4 | |
| SCHEMBL5457744 | 0.82 | GRIA2 (0.70) | GRIA2KCNH2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | claimed |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-06-12 | — | — | US | disclosed |
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | BDNF, MECP2, NTRK2 | GRIA2 43/4885KCNH2 4187/4885GRIA4 53/4885 |
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GRM3, GLRA3, GLRA1 | GRIA2 34/4885KCNH2 562/4885GRIA4 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.